Eversense E3 CGM now connects with Apple Health!
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a Health Care Provider. The Eversense CGM System is a prescription device; patients should talk to their Health Care Provider to learn more. For important safety information, see Safety Information.
Eversense, Eversense Continuous Glucose Monitoring, Eversense CGM, Eversense Sensor, Eversense Smart Transmitter, Eversense App and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
Other brands and their products are trademarks or registered trademarks of their respective holders.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System.
Android is a trademark of Google LLC.
© 2021 Senseonics, Incorporated. All rights reserved.
© 2021 Ascensia Diabetes Care Holdings AG. All rights reserved.